When a Compounded GLP-1 Is Not the Right Choice
Compounded GLP-1 medications are not for everyone. This page covers the situations where the answer is no, or not yet, so you can decide whether a consultation is worth booking.
Updated November 11, 2026 · Part of our care guide (Compare) · Educational information, not medical advice.
Where these rules come from
Compounded medications have no FDA label of their own, because they are not FDA approved. The closest official reference is the prescribing information for the FDA-approved products with the same active ingredients: tirzepatide and semaglutide for chronic weight management. The points below come from those labels and from the FDA's page on unapproved GLP-1 drugs. Your provider applies them to your own history.
A personal or family history of thyroid cancer (MTC) or MEN 2
Both labels carry a boxed warning, the FDA's most serious kind. In rodents, both medicines caused thyroid C-cell tumors; whether they do so in people is not known. Both are contraindicated, meaning they should not be used, if you have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN 2).
If you are not sure about your family history, find out before your consultation. The labels list a lump in the neck, trouble swallowing, shortness of breath and persistent hoarseness as symptoms to report.
A serious allergic reaction to the medicine
Both labels list a known serious hypersensitivity to the medicine, or to an ingredient in it, as a contraindication. Serious reactions, including anaphylaxis and angioedema, have been reported.
Pregnancy, planning a pregnancy, and breastfeeding
- Pregnancy: both labels say weight loss offers no benefit during pregnancy and may cause fetal harm, and to stop the medicine once a pregnancy is recognized.
- Planning a pregnancy: the semaglutide label advises stopping at least 2 months before a planned pregnancy, because the medicine stays in the body a long time.
- Birth control pills: the tirzepatide label says it may make oral hormonal contraceptives less effective. It advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
- Breastfeeding: neither label has data on the injected medicine in breast milk. That is a conversation to have with your provider before starting.
Conditions that need extra care
These are not always a no, but each one needs a careful conversation first:
- Severe gastroparesis (very slow stomach emptying): both labels say the medicines are not recommended.
- A past pancreatitis: acute pancreatitis, sometimes severe, has been seen in people taking these medicines. Persistent, severe abdominal pain, sometimes spreading to the back, is a reason to stop and contact your clinician.
- Planned surgery or sedation: both labels warn about pulmonary aspiration during general anesthesia or deep sedation, and tell patients to inform their care team before any planned surgery or procedure.
- Type 2 diabetes with diabetic retinopathy: the labels ask for monitoring in people with a history of retinopathy.
- Another GLP-1 or tirzepatide product: the tirzepatide label says it should not be combined with other tirzepatide products or any GLP-1 receptor agonist.
When an FDA-approved product fits better
Compounded medications are prescribed when a patient has a clinical need that a commercially available product does not meet, a determination Charles Ortega, PA-C makes based on your individual health profile. Price is not a clinical need.
The FDA-approved products have been reviewed by the FDA for safety, effectiveness and quality; compounded drugs have not. If an approved product meets your needs, that is usually the better route. It is worth asking your insurer whether your plan covers one; our article on insurance coverage for GLP-1 medications explains how to ask.
When care without medication is the better start
The FDA-approved products are for adults with obesity, or adults with overweight plus at least one weight-related health condition, and always alongside a reduced-calorie diet and more physical activity. In the main trials, obesity meant a BMI of 30 or higher and overweight meant 27 or higher.
If you are outside those groups, or you would simply rather not take a medication, a GLP-1 is not the place to start. Nutrition, activity and treating related conditions such as high blood pressure come first, and they still matter if you do take a medication later. Our article on medical weight loss vs. going it alone covers the options.
If you are still unsure
A consultation is the place to work it out. Charles Ortega, PA-C reviews your history, examines you and screens for everything on this page. If a compounded GLP-1 is not right for you, he will say so and explain the alternatives. See what happens at your first visit.
Next step · Decide
Your first weight management visit
What the consultation covers, and how Charles decides whether a medication fits you.
Frequently asked questions
Sources
- FDA prescribing information, tirzepatide injection for chronic weight management, NDA 217806 (revised April 2026)
- FDA prescribing information, semaglutide injection for chronic weight management, NDA 215256 (revised January 2026)
- U.S. Food and Drug Administration: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026)
Related reading
See every page in our care guide, grouped by where you are: learning, comparing or ready to decide.
Not sure where you fit?
Book a consultation with Charles Ortega, PA-C. He reviews your history and tells you plainly whether a compounded GLP-1 makes sense for you.